Disrupting Conventional Approaches to CAR-T Cell Therapies with our Proprietary Technology Platform—FasTCAR
Time: 4:00 pm
day: Day One
Details:
- Exploring CD19/BCMA CAR-T for treating B-cell Non-Hodgkin Lymphoma and CD19 CAR-T for treating Adult Acute Lymphoblastic Leukemia
- Latest data, potential and future direction
